PMID- 37668418
OWN - NLM
STAT- MEDLINE
DCOM- 20231010
LR  - 20231018
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 31
IP  - 9
DP  - 2023 Oct 1
TI  - Hypoxia-inducible Factor-1alpha and mTOR as a Potential Therapeutic Target in 
      Endometriosis: An Immunohistochemical Study.
PG  - 629-634
LID - 10.1097/PAI.0000000000001148 [doi]
AB  - BACKGROUND AND STUDY AIM: We aim to study the immunohistochemical expression of 
      both hypoxia-inducible factor-1alpha (HIF-1alpha) and mammalian target of rapamycin 
      (mTOR) in endometriosis to provide new evidence for a targeted endometriosis 
      therapy. PATIENTS AND METHODS: This study comprised 106 endometriotic cases 
      diagnosed clinically and histopathologically. The immunohistochemical method was 
      done to determine the expression of HIF-1alpha and mTOR. RESULTS: Endometriotic 
      glands showed significant cytoplasmic expression of both markers in patients with 
      poor ovulation, severe endometriosis, and infertile for >2 years ( P <0.001). 
      Also, patients with intense and worst pain show significant immunohistochemical 
      expression of both markers ( P <0.001). There is a significant correlation 
      between mTOR and HIF-1alpha expression in endometriotic tissue samples as P <0.001. 
      CONCLUSIONS: Our data suggest that both mTOR and its downstream target HIF-1alpha 
      transcription factor are both disrupted in patients with endometriosis, which is 
      consistent with aberrant activation of these pathways and their possible 
      contribution to the pathogenesis of endometriosis. These results could offer a 
      promising novel opportunity to be blocked therapeutically. As new management 
      options need to be refined in particular in severe cases and infertile patients 
      with endometriosis, therefore future studies are warranted to investigate 
      treating endometriosis with mTOR inhibitors; the latter are already in clinical 
      trials in phase III and IV, treating solid tumors as well as non-neoplastic 
      disorders.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Badary, Dalia M
AU  - Badary DM
AD  - Obstetrics and Gynecology, Faculty of Medicine, Assiut University.
FAU - Abou-Taleb, Hisham A
AU  - Abou-Taleb HA
AD  - Obstetrics and Gynecology, Faculty of Medicine, Assiut University.
FAU - Ibrahim, Maha
AU  - Ibrahim M
AD  - Department of Cancer Pathology, South Egypt Cancer Institute, Assiut University, 
      Assiut, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20230830
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Endometriosis/pathology
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Gene Expression Regulation
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/05 12:42
MHDA- 2023/10/10 06:41
CRDT- 2023/09/05 09:13
PHST- 2022/03/23 00:00 [received]
PHST- 2023/08/01 00:00 [accepted]
PHST- 2023/10/10 06:41 [medline]
PHST- 2023/09/05 12:42 [pubmed]
PHST- 2023/09/05 09:13 [entrez]
AID - 00129039-990000000-00122 [pii]
AID - 10.1097/PAI.0000000000001148 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2023 Oct 1;31(9):629-634. doi: 
      10.1097/PAI.0000000000001148. Epub 2023 Aug 30.